Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

MLA

Dimopoulos, M. A.Lonial, S.White, D.Moreau, P.Weisel, K.San-Miguel, J.Shpilberg, O.Grosicki, S.Špička, I.Walter-Croneck, A.Magen, H.Mateos, M. V.Belch, A.Reece, D.Beksac, M.Spencer, A.Oakervee, H.Orlowski, R. Z.Taniwaki, M.Röllig, C.Einsele, H.Matsumoto, M.Wu, K. L.Anderson, K. C.Jou, Y. M.Ganetsky, A.Singhal, A. K.Richardson, P. G. Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results from the Phase 3 Randomized ELOQUENT-2 Study. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1478880906&authtype=sso&custid=ns315887.

APA

Dimopoulos, M. A. L. S. W. D. M. P. W. K. S.-M. J. S. O. G. S. S. I. W.-C. A. M. H. M. M.-V. B. A. R. D. B. M. S. A. O. H. O. R. Z. T. M. R. C. E. H. M. M. W. K. L. A. K. C. J. Y.-M. G. A. S. A. K. R. P. G. (2020). Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

Chicago

Dimopoulos, M.A. Lonial, S. White, D. Moreau, P. Weisel, K. San-Miguel, J. Shpilberg, O. Grosicki, S. Špička, I. Walter-Croneck, A. Magen, H. Mateos, M.-V. Belch, A. Reece, D. Beksac, M. Spencer, A. Oakervee, H. Orlowski, R.Z. Taniwaki, M. Röllig, C. Einsele, H. Matsumoto, M. Wu, K.L. Anderson, K.C. Jou, Y.-M. Ganetsky, A. Singhal, A.K. Richardson, P.G. 2020. “Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results from the Phase 3 Randomized ELOQUENT-2 Study.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1478880906&authtype=sso&custid=ns315887.